Wyzer Biosciences

Executive Summary

Wyzer Biosciences, founded in 2011 and headquartered in Cambridge, MA, is a full-service DNA sequencing and preparation provider serving the biotechnology and research sectors. With over 100 years of combined scientific expertise and more than 60 publications, the company offers both Sanger and next-generation sequencing (NGS) services, along with DNA prep solutions. Despite being categorized under AI/ML, Drug Delivery, and Biologics, its core business is as a contract research organization (CRO) supporting genomics research. Wyzer differentiates itself through personalized service and deep domain knowledge, catering to academic, pharmaceutical, and biotech clients. As a private company without disclosed funding or valuation, it operates in a competitive landscape dominated by larger players like Illumina and Thermo Fisher, yet maintains a niche by focusing on high-touch, custom workflows.

Upcoming Catalysts (preview)

• Q3 2026Launch of Enhanced NGS Service with AI-Driven Data Analysis65% success
• Q4 2026Strategic Partnership with Major Pharmaceutical Company for Clinical Sequencing50% success
• Q2 2026Expansion of Laboratory Facility to Increase Capacity80% success